Literature DB >> 25027280

Lymph node involvement in colon cancer patients decreases with age; a population based analysis.

H Khan1, Adam J Olszewski2, P Somasundar3.   

Abstract

BACKGROUND: The variation in nodal involvement between age groups has not been thoroughly studied in colon cancer, but it may affect strategies for extent of resection in elderly patients. The objective of our study was to compare nodal involvement in colon cancer patients, with a focus on surgical staging practices in the elderly.
METHODS: We extracted data from the Surveillance, Epidemiology and End Results registry on 208,077 patients diagnosed with stage I-III colon adenocarcinoma between 2000 and 2010. Patients undergoing colon resection, patients with adequate staging with ≥12 lymph nodes examined (LNE, n = 114,351) and with node-positive cancers were compared in age groups using chi-squared test. Relative risk (RR) of node-positive cancer was compared in a multivariable log-linear model, and relative survival in a flexible parametric model.
RESULTS: While the rates of colon resection were similar in all age groups, older patients were significantly less likely to have ≥12 LNE (P < 0.0001). When adequately staged, older patients had a significantly lower proportion of node-positive cancers (P < 0.0001). Survival was better in patients with ≥12 LNE, with no significant difference in the benefit between the age groups (P = 0.25).
CONCLUSIONS: When adequately staged, older patients are less likely to have node positive colon cancer, which may help them avoid adjuvant chemotherapy. Since the survival benefit of adequate nodal staging is similar in every age group, the guidelines for extent of resection and pathological examination should be diligently adhered to in all patients undergoing curative surgery, regardless of age.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Colon cancer; Lymph node involvement; Older patients

Mesh:

Year:  2014        PMID: 25027280     DOI: 10.1016/j.ejso.2014.06.002

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  7 in total

1.  The re-evaluation of optimal lymph node yield in stage II right-sided colon cancer: is a minimum of 12 lymph nodes adequate?

Authors:  Yibo Cai; Guoping Cheng; Xingang Lu; Haixing Ju; Xiu Zhu
Journal:  Int J Colorectal Dis       Date:  2020-01-30       Impact factor: 2.571

Review 2.  Stage migration vs immunology: The lymph node count story in colon cancer.

Authors:  Bruno Märkl
Journal:  World J Gastroenterol       Date:  2015-11-21       Impact factor: 5.742

3.  Age and Lymph Node Positivity in Patients With Colon and Rectal Cancer in the US Military Health System.

Authors:  Melannie S Alexander; Jie Lin; Craig D Shriver; Katherine A McGlynn; Kangmin Zhu
Journal:  Dis Colon Rectum       Date:  2020-03       Impact factor: 4.412

4.  Reconsideration of the optimal minimum lymph node count for young colon cancer patients: a population-based study.

Authors:  Xu Guan; Yuliuming Wang; Hanqing Hu; Zhixun Zhao; Zheng Jiang; Zheng Liu; Yinggang Chen; Guiyu Wang; Xishan Wang
Journal:  BMC Cancer       Date:  2018-06-01       Impact factor: 4.430

5.  Retrospective Cohort Analysis of the Effect of Age on Lymph Node Harvest, Positivity, and Ratio in Colorectal Cancer.

Authors:  Samara L Lewis; Kenneth E Stewart; Tabitha Garwe; Zoona Sarwar; Katherine T Morris
Journal:  Cancers (Basel)       Date:  2022-08-06       Impact factor: 6.575

6.  Exploration of the Optimal Minimum Lymph Node Count after Colon Cancer Resection for Patients Aged 80 Years and Older.

Authors:  Xu Guan; Wei Chen; Zheng Jiang; Zheng Liu; Dazhuang Miao; Hanqing Hu; Zhixun Zhao; Runkun Yang; Xishan Wang
Journal:  Sci Rep       Date:  2016-12-12       Impact factor: 4.379

Review 7.  Patterns of age disparities in colon and lung cancer survival: a systematic narrative literature review.

Authors:  Sophie Pilleron; Helen Gower; Maryska Janssen-Heijnen; Virginia Claire Signal; Jason K Gurney; Eva Ja Morris; Ruth Cunningham; Diana Sarfati
Journal:  BMJ Open       Date:  2021-03-10       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.